The Journal of Urology
Volume 182, Issue 3 , Pages 900-906 , September 2009

Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration

  • Nicholas J. Hellenthal

      Affiliations

    • University of California-Davis, Sacramento, California
    • Corresponding Author InformationCorrespondence: Department of Urology, 4860 Y St., Suite 3500, University of California-Davis Medical Center, Sacramento, California 95817 (telephone: 916-734-2893; FAX: 916-734-8094)
    • ,
  • Shahrokh F. Shariat

      Affiliations

    • University of Texas Southwestern, Dallas, Texas
    • ,
  • Vitaly Margulis

      Affiliations

    • University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Pierre I. Karakiewicz

      Affiliations

    • University of Montreal, Montreal, Quebec, Canada
    • ,
  • Marco Roscigno

      Affiliations

    • University of Vienna, Vienna, Austria
    • ,
  • Christian Bolenz

      Affiliations

    • University of Texas Southwestern, Dallas, Texas
    • Universitatsklinikum Mannheim, Mannheim, Germany
    • ,
  • Mesut Remzi

      Affiliations

    • Vita-Salute University, Milan, Italy
    • ,
  • Alon Weizer

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • ,
  • Richard Zigeuner

      Affiliations

    • Medical University Graz, Graz, Austria
    • ,
  • Karim Bensalah

      Affiliations

    • University of Rennes, Rennes, France
    • ,
  • Casey K. Ng

      Affiliations

    • Cornell University, New York, New York
    • ,
  • Jay D. Raman

      Affiliations

    • Cornell University, New York, New York
    • ,
  • Eiji Kikuchi

      Affiliations

    • Keio University School of Medicine, Tokyo, Japan
    • ,
  • Francesco Montorsi

      Affiliations

    • Vita-Salute University, Milan, Italy
    • ,
  • Mototsugu Oya

      Affiliations

    • Keio University School of Medicine, Tokyo, Japan
    • ,
  • Christopher G. Wood

      Affiliations

    • University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with Antigenics, Pfizer, Bayer/Onyx, Kidney Cancer Association and Ethicon.
    • ,
  • Mario Fernandez

      Affiliations

    • Clinica Alemana de Santiago, Santiago de Chile, Chile
    • ,
  • Christopher P. Evans

      Affiliations

    • University of California-Davis, Sacramento, California
    • ,
  • Theresa M. Koppie

      Affiliations

    • University of California-Davis, Sacramento, California

Received 16 December 2008

References 

  1. Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol. 2007;4:432
  2. Hall MC, Womack S, Sagalowsky AI, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594
  3. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium (Efficacy and patterns of response and relapse). Cancer. 1989;64:2448
  4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859
  5. Lehmann J, Retz M, Wiemers C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol. 2005;23:4963
  6. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989;142:289
  7. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer. 1988;62:2016
  8. Charbit L, Gendreau MC, Mee S, et al. Tumors of the upper urinary tract: 10 years of experience. J Urol. 1991;146:1243
  9. Lee SH, Lin JS, Tzai TS, et al. Prognostic factors of primary transitional cell carcinoma of the upper urinary tract. Eur Urol. 1996;29:266
  10. Igawa M, Urakami S, Shiina H, et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int. 1995;55:74
  11. Bolenz C, Fernández MI, Trojan L, et al. Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma. Urology. 2008;72:364
  12. Lee SE, Byun SS, Park YH, et al. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int. 2006;77:22
  13. Kwak C, Lee SE, Jeong IG, et al. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology. 2006;68:53
  14. Michael M, Tannock IF, Czaykowski PM, et al. Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. Br J Urol. 1998;82:366
  15. Bamias A, Deliveliotis C, Fountzilas G, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:2150
  16. Huang WC, Sevey AS, Serio AM, et al. Chronic renal disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncology. 2006;7:735
  17. Hochster HS, Luo W, Popa EC, et al. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol. 2007;25:5397
  18. Langer C, Li S, Schiller J, et al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol. 2007;25:418
  19. Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003;98:1620
  20. Novara G, De Marco V, Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer. 2007;110:1715

 Study received institutional review board approval.

PII: S0022-5347(09)01151-3

doi: 10.1016/j.juro.2009.05.011

The Journal of Urology
Volume 182, Issue 3 , Pages 900-906 , September 2009

Article Tools

* Image Usage & Resolution